Barinthus Bio reports Q3 net loss $14.1M; cash $160.3M, runway to Q2 2025

Barinthus Biotherapeutics plc.

2023-Q3 EPS reported -$1.46 revenue$802,000

Net loss of $14.1M ($0.37 per share) in Q3 2023, compared to $23.8M loss ($0.62 per share) in Q2 2023.
Cash and cash equivalents $160.3M as of Sep 30, 2023; expects runway into Q2 2025.
R&D expenses $15.1M in Q3, up from $13.5M in Q2, driven by VTP-300 HBV and VTP-850 trials.
Upcoming milestones: interim data from two Phase 2 HBV trials at AASLD Nov 2023; Australia submission for VTP-1000 (celiac).
Company changed name from Vaccitech to Barinthus Biotherapeutics in Nov 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Barinthus Biotherapeutics plc. reported third quarter of 2023 results: net income $14.1 million, EPS $0.37 per share on both basic and fully diluted bases.

Period: third quarter of 2023
Net income: $14.1 million
EPS: $0.37 per share on both basic and fully diluted bases
Result: reported results

Exact text from the filing

For the third quarter of 2023, the Company generated a net loss attributable to its shareholders of $14.1 million, or $0.37 per share on both basic and fully diluted bases, compared to a net loss attributable to shareholders of $23.8 million, or $0.62 per share on both basic and fully diluted bases in the second quarter of 2023.

View on SEC.gov

Browse all earnings releases →

Barinthus Biotherapeutics plc. filing history →

Source: SEC EDGAR

accession 0001104659-23-116280

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.